AKT1 and glioblastoma: Since current standard of care for patients with GBM includes IR, which is a strong activator of the PI3-K/AKT and MAPK/ERK pathways and promote radio-resistance by activation of the DNA damage response [62,63], it would be interesting or even necessary to include IR in future combinatorial treatment studies.